Cargando…

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry

BACKGROUND: Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation, caused by a deficiency of iduronate-2-sulfatase (I2S). Enzyme replacement therapy (ERT) with recombinant idursulfase (IDS), the standard of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Racoma, Marie Julianne C., Calibag, Maria Kristina Karizza B., Cordero, Cynthia P., Abacan, Mary Ann R., Chiong, Mary Anne D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293534/ https://www.ncbi.nlm.nih.gov/pubmed/34289859 http://dx.doi.org/10.1186/s13023-021-01875-5

Ejemplares similares

Genetic and clinical characteristics of Filipino patients with Gaucher disease
por: Chiong, Mary Anne D., et al.
Publicado: (2018)

Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome
por: Chiong, Mary Anne D., et al.
Publicado: (2017)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
por: Calias, Pericles, et al.
Publicado: (2012)

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
por: Hogan, Melissa J., et al.
Publicado: (2020)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Comparative study of idursulfase beta and idursulfase in vitro and in vivo
por: Kim, Chihwa, et al.
Publicado: (2017)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response
por: Killedar, Smruti, et al.
Publicado: (2010)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration
por: Chung, Jou-Ku, et al.
Publicado: (2016)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Carnitine-acylcarnitine Translocase Deficiency with c.199-10T>G Mutation in Two Filipino Neonates Detected through Parental Carrier Testing
por: Carmona, Suzanne Marie G., et al.
Publicado: (2023)

Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases
por: Belfiore, Maria Paola, et al.
Publicado: (2020)

Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II
por: Kim, Katherine H., et al.
Publicado: (2014)

Pharmacokinetics and Bioavailability of a Therapeutic Enzyme (Idursulfase) in Cynomolgus Monkeys after Intrathecal and Intravenous Administration
por: Xie, Hongsheng, et al.
Publicado: (2015)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
por: Yee, Karen S., et al.
Publicado: (2023)

Rubinstein–Taybi Syndrome in a Filipino Infant with a Novel CREBBP Gene Pathogenic Variant
por: Yumul, Rhea Camille R., et al.
Publicado: (2022)

Plasma amino acid and urine organic acid profiles of Filipino patients with maple syrup urine disease (MSUD) and correlation with their neurologic features
por: Chiong, Mary Anne D., et al.
Publicado: (2016)

Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI
por: Tessitore, Alessandra, et al.
Publicado: (2009)

Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry
por: Polgreen, Lynda E., et al.
Publicado: (2022)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Radical surgery for primary thyroid lymphoma in a Filipino female: Report of a case and review of literature
por: Perez, Anthony R., et al.
Publicado: (2020)

The Role of Dimethyl Sulfoxide (DMSO) in Gene Expression Modulation and Glycosaminoglycan Metabolism in Lysosomal Storage Disorders on an Example of Mucopolysaccharidosis
por: Moskot, Marta, et al.
Publicado: (2019)

Clinical outcomes of laminoplasty for patients with lysosomal storage disease including mucopolysaccharidosis and mucolipidoses: a retrospective cohort study
por: Terai, Hidetomi, et al.
Publicado: (2021)

Airway Findings in Patients with Hunter Syndrome Treated with Intravenous Idursulfase
por: De Vuyst, Richard, et al.
Publicado: (2023)

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2019)

Adults with lysosomal storage diseases in the undiagnosed diseases network
por: Xiao, Changrui, et al.
Publicado: (2022)

Lysosomes and Lysosomal Storage Diseases
por: Noebels, Jeffrey L.
Publicado: (1981)

Crosstalk between 2 organelles: Lysosomal storage of heparan sulfate causes mitochondrial defects and neuronal death in mucopolysaccharidosis III type C
por: Pshezhetsky, Alexey V
Publicado: (2015)

Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II
por: Ngu, Lock-Hock, et al.
Publicado: (2017)

Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neurons
por: Bayó-Puxan, Neus, et al.
Publicado: (2018)

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
por: Hollak, Carla EM, et al.
Publicado: (2011)

Lysosomal storage disorders
por: Cabrera-Salazar, Mario A, et al.
Publicado: (2007)

Lysosomal storage diseases
por: Ferreira, Carlos R., et al.
Publicado: (2017)

Determining Filipino Normative Data for a Battery of Neuropsychological Tests: The Filipino Norming Project (FNP)
por: Dominguez, Jacqueline Cotoong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4u9aadvd2v0ra2jkqvvgc7s07u